Navamedic and Orion Corporation Sign License & Supply Agreement for Flexilev in Europe
Navamedic and Orion Corporation Sign License & Supply Agreement for Flexilev in Europe
OSLO, Norway, June 24, 2024 /PRNewswire/ -- Navamedic ASA and Orion Corporation ("Orion") have today signed a license and supply agreement for Flexilev, including the OraFID dispenser, across Europe, not including Sweden, Norway, Denmark, and Iceland, where Navamedic will market and sell the product. Flexilev is a novel prescription treatment for Parkinson's disease and was added to Navamedic's product portfolio following the acquisition of Sensidose AB in May 2023.
挪威奧斯陸，2024年6月24日/美通社/--Navamedic ASA和Orion Corporation（"Orion"）今天簽署了一份歐洲Flexilev的許可和供應協議，不包括瑞典、挪威、丹麥和冰島，在這些地區Navamedic將推廣和銷售該產品。Flexilev是一種獨特的帕金森病處方治療藥物，是自2023年5月收購Sensidose AB後加入Navamedic的產品組合。
Through the signed agreement, Orion has been granted the exclusive right to market, distribute, and sell Flexilev in 27 countries in Europe, including the "big five": Germany, France, Italy, Spain and the UK. Orion will be the marketing authorization (MA) holder in their territory and assume all rights and responsibilities as the MA holder. Navamedic will be responsible for manufacturing and supply of Flexilev in the OraFID dispenser to Orion.
通過簽署的協議，Orion已獲得在歐洲27個國家，包括“五個大國”--德國、法國、意大利、西班牙和英國市場，分銷和銷售Flexilev的獨家權利。Orion將在其領地擁有市場授權（MA）持有人的權利和責任。Navamedic將負責在OraFID分配器中製造和供應Flexilev。
"The agreement with Orion to market and sell Flexilev in Europe represents a major milestone as part of the commercialization strategy for Flexilev. Since acquiring the product last year, we have identified several significant growth opportunities for Flexilev, with focus on signing an agreement for Europe where we already have sales in our home turf Scandinavia and marketing authorizations in several other countries. Orion has long-standing experience in the field of neurological diseases and has paved the way for Parkinson's disease treatment in Europe, making it a strong commercial partner that matches Navamedic's ambition for Flexilev," says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
"與Orion在歐洲市場和銷售Flexilev的協議代表了Flexilev商業化戰略的重要里程碑。自去年收購該產品以來，我們已經確定了Flexilev的多個重大增長機會，重點是簽署歐洲協議，在我們的母國斯堪的納維亞地區已經擁有銷售額和在其他幾個國家擁有市場授權。Orion在神經系統疾病領域擁有悠久的經驗，爲歐洲帕金森病治療鋪平了道路，成爲一個與Navamedic的Flexilev雄心相匹配的強大商業夥伴"，Navamedic ASA首席執行官Kathrine Gamborg Andreassen表示。
"This agreement will enable Orion to broaden our Parkingson's Disease portfolio and extend treatment offering to suitable advanced stage patients in Europe", says Hao Pan, SVP of Branded Products, Orion.
"這項協議將使Orion擴大我們的帕金森病產品組合，並向歐洲適合的晚期患者提供擴展治療選擇"，Orion的品牌產品高級副總裁Hao Pan表示。
The agreement consists of a non-refundable upfront payment of 2mEUR to Navamedic, upon signature of the agreement. Additionally, Navamedic is entitled to milestone payments of up to 3.5 mEUR upon reimbursement approval in key countries, as well as royalty from net revenue and sales milestone payments.
協議包括一項2mEUR的不可退款預付款，協議簽署時支付。此外，Navamedic有權獲得多達3.5mEUR的具有關鍵國家報銷批准的里程碑付款，以及來自淨收入和銷售里程碑付款的版稅。
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: [email protected]
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: [email protected]
如需更多信息，請聯繫：
Navamedic首席執行官Kathrine Gamborg Andreassen
手機號：+47 951 78 680
電郵：[email protected]
Navamedic首席財務官Lars Hjarrand
手機號：+47 917 62 842
電子郵件：[email protected]
About Navamedic
關於Navamedic
Navamedic is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet consumer needs and current public health concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to empower people to live healthier and more fulfilling lives. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit Navamedic.com.
Navamedic是一家北歐製藥公司，致力於通過成爲高質量處方、消費健康和醫院產品的可靠供應商，提高人們的生活質量。我們精心挑選了不斷增長的產品組合，以滿足消費者需求和當前公共衛生問題，如肥胖症、帕金森病和胃腸相關疾病，讓人們擁有更健康、更充實的生活。Navamedic總部位於挪威奧斯陸，股票在奧斯陸證券交易所上市（股票代碼：NAVA）。欲了解更多信息，請訪問Navamedic.com。
About Flexilev
關於Flexilev
Flexilev was developed by Sensidose AB and is prescription treatment for advanced Parkinson's diases. It contains two active substances, levodopa and karbidopa, and is administered as micro tables through Orafid, a tablet delivery device. With the combination of Flexilev and Orafid, patients receive individualized treatment and are provided with the correct dose at the correct time.
Flexilev是由Sensidose AB開發的一種處方治療先進帕金森病。其包含兩種活性物質：左旋多巴和卡比多巴，通過Orafid，一種片劑輸送裝置，以微量的方式進行給藥。Flexilev和Orafid的結合使患者能夠接受個性化治療，並在正確的時間獲得正確的劑量。
About Orion Corporation
關於Orion Corporation
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
Orion是一家在全球範圍內運營的芬蘭製藥公司,致力於創造健康。我們開發、製造和銷售人類和獸醫藥品以及活性藥品成分。Orion擁有廣泛的專有和通用藥品和消費品，我們的藥品研發的核心治療領域是腫瘤學和疼痛學。Orion開發的專有產品用於治療癌症、神經系統疾病和呼吸系統疾病，等等。2023年，Orion的淨銷售額爲11.9億歐元，公司年底有大約3,600名員工。Orion的A股和B股在赫爾辛基納斯達克股票交易所上市。
This information was brought to you by Cision
本信息由Cision提供